These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 26155003

  • 21. Establishing the role of tigecycline in an era of antimicrobial resistance.
    Schafer JJ, Goff DA.
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395
    [Abstract] [Full Text] [Related]

  • 22. An essential requirement for the licensing of new antibiotics is the provision of data on efficacy and safety obtained from clinical trials in which patients are randomized to receive either the experimental drug or a comparator antibiotic regarded as a standard treatment option. Preface.
    Johnson AP, Leibovici L.
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii1. PubMed ID: 23930279
    [No Abstract] [Full Text] [Related]

  • 23. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
    Bradford PA, Weaver-Sands DT, Petersen PJ.
    Clin Infect Dis; 2005 Sep 01; 41 Suppl 5():S315-32. PubMed ID: 16080070
    [Abstract] [Full Text] [Related]

  • 24. Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial.
    Qvist N, Warren B, Leister-Tebbe H, Zito ET, Pedersen R, McGovern PC, Babinchak T.
    Surg Infect (Larchmt); 2012 Apr 01; 13(2):102-9. PubMed ID: 22439781
    [Abstract] [Full Text] [Related]

  • 25. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections.
    Falagas ME, Vardakas KZ, Tsiveriotis KP, Triarides NA, Tansarli GS.
    Int J Antimicrob Agents; 2014 Jul 01; 44(1):1-7. PubMed ID: 24602499
    [Abstract] [Full Text] [Related]

  • 26. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections.
    Grolman DC.
    Int J Infect Dis; 2007 May 01; 11 Suppl 1():S7-15. PubMed ID: 17603950
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
    Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E, Loh E, Rose G.
    Int J Infect Dis; 2005 Sep 01; 9(5):251-61. PubMed ID: 16099700
    [Abstract] [Full Text] [Related]

  • 28. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials.
    Gardiner D, Dukart G, Cooper A, Babinchak T.
    Clin Infect Dis; 2010 Jan 15; 50(2):229-38. PubMed ID: 20025527
    [Abstract] [Full Text] [Related]

  • 29. Methicillin-resistant Staphylococcus aureus infection epidemiology and clinical response from tigecycline soft tissue infection trials.
    Puzniak LA, Quintana A, Wible M, Babinchak T, McGovern PC.
    Diagn Microbiol Infect Dis; 2014 Jun 15; 79(2):261-5. PubMed ID: 24725736
    [Abstract] [Full Text] [Related]

  • 30. Evaluation of Tigecycline Efficacy and Post-Discharge Outcomes in a Clinical Practice Population with Complicated Intra-Abdominal Infection: A Propensity Score-Matched Analysis.
    Solomkin J, Mullins CD, Quintana A, Eckmann C, Shelbaya A, Ernst FR, Krukas MR, Reisman A.
    Surg Infect (Larchmt); 2016 Aug 15; 17(4):402-11. PubMed ID: 26981640
    [Abstract] [Full Text] [Related]

  • 31. Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective.
    Teras J, Gardovskis J, Vaasna T, Kupcs U, Pupelis G, Dukart G, Dartois N, Jouve S, Cooper A, 305 Study Group.
    J Chemother; 2008 Oct 15; 20 Suppl 1():20-7. PubMed ID: 19036671
    [Abstract] [Full Text] [Related]

  • 32. All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials.
    McGovern PC, Wible M, El-Tahtawy A, Biswas P, Meyer RD.
    Int J Antimicrob Agents; 2013 May 15; 41(5):463-7. PubMed ID: 23537581
    [Abstract] [Full Text] [Related]

  • 33. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections.
    Van Wart SA, Owen JS, Ludwig EA, Meagher AK, Korth-Bradley JM, Cirincione BB.
    Antimicrob Agents Chemother; 2006 Nov 15; 50(11):3701-7. PubMed ID: 16940069
    [Abstract] [Full Text] [Related]

  • 34. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].
    Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM, Babinchak T, Ellis-Grosse EJ, Loh E, 301 Study Group.
    BMC Infect Dis; 2005 Oct 19; 5():88. PubMed ID: 16236177
    [Abstract] [Full Text] [Related]

  • 35. Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin.
    Mallick R, Sun S, Schell SR.
    Surg Infect (Larchmt); 2007 Apr 19; 8(2):159-72. PubMed ID: 17437361
    [Abstract] [Full Text] [Related]

  • 36. Tigecycline: a critical update.
    Shakil S, Akram M, Khan AU.
    J Chemother; 2008 Aug 19; 20(4):411-9. PubMed ID: 18676218
    [Abstract] [Full Text] [Related]

  • 37. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience.
    Fomin P, Koalov S, Cooper A, Babinchak T, Dartois N, De Vane N, Castaing N, Tellado J, 301 And 306 Study Groups.
    J Chemother; 2008 Oct 19; 20 Suppl 1():12-9. PubMed ID: 19036670
    [Abstract] [Full Text] [Related]

  • 38. Tigecycline: a new antibiotic.
    Hylands J.
    Intensive Crit Care Nurs; 2008 Aug 19; 24(4):260-3. PubMed ID: 18554910
    [Abstract] [Full Text] [Related]

  • 39. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
    Popejoy MW, Long J, Huntington JA.
    BMC Infect Dis; 2017 May 02; 17(1):316. PubMed ID: 28464828
    [Abstract] [Full Text] [Related]

  • 40. Tigecycline-induced acute pancreatitis: case report and literature review.
    Hung WY, Kogelman L, Volpe G, Iafrati M, Davidson L.
    Int J Antimicrob Agents; 2009 Nov 02; 34(5):486-9. PubMed ID: 19540093
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.